Up to $A3.73M if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $A29.8M in the first 12 months or $A1.8M if gross revenue from product sales exceed $A22.4M in the first 12 months
Up to $A3.73M if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $A44.7M in the second 12 months or $A1.8M if gross revenue from product sales exceed $A33.5M in the second 12 months
Gross revenue - the catch word
Who fix the price of the product? I think it’s LeMaitre.
Wouldn’t they like to provide heavy discount to the product purchasers? In doing so, not only the product get sold like a hot cake (with their marketing channel) and make greater awareness about the product but also do not need to pay AHZ a buck.
I highly doubt AHZ will get any coins from this arrangement.
cheers
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
Up to $A3.73M if gross revenue from LeMaitre CardioCel® and...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M |
Open | High | Low | Value | Volume |
$15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 779 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280 | 15.100 |
2 | 96 | 15.020 |
1 | 15 | 15.010 |
2 | 582 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 779 | 1 |
15.930 | 250 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
16.000 | 1250 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |